What's Happening?
Ollin Biosciences has raised $330 million in a Series B funding round to advance its VEGF/Ang2 antibody, OLN324, into Phase 3 trials. The funding follows positive results from a Phase 1b study where OLN324 outperformed Genentech's Vabysmo in treating
diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The antibody showed faster and greater improvements in anatomical outcomes and vision gains, with fewer retreatments required. The funding round was co-led by TCGX and ARCH Venture Partners, with participation from investors such as a16z Bio+Health and Blackstone Multi-Asset Investing. Ollin plans to begin late-stage testing for OLN324 by the end of the year.
Why It's Important?
The successful funding round highlights the potential of OLN324 to become a significant treatment option for eye diseases like DME and AMD, which are leading causes of vision loss. By outperforming an established therapy like Vabysmo, Ollin's antibody could offer improved outcomes for patients and reduce the frequency of treatments. The investment also reflects confidence in Ollin's approach to developing bispecific therapies for eye diseases. If successful, OLN324 could capture a substantial share of the eye disease treatment market, benefiting patients and healthcare providers.
What's Next?
Ollin plans to initiate Phase 3 trials for OLN324 in the second half of the year, focusing on both DME and AMD. The company will also use remaining funds to advance its TSHR/IGF-1R bispecific antibody, OLN102, for thyroid eye disease and Graves' disease. As Ollin progresses with its clinical trials, it will engage with regulatory agencies to ensure compliance and facilitate the approval process. The outcomes of these trials will be closely watched by investors and the medical community, as they could lead to new treatment options for patients with eye diseases.
